Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Page 1
Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review.
Waheed W, Newman E, Aboukhatwa M, Moin M, Tandan R. Waheed W, et al. Among authors: tandan r. Ther Clin Risk Manag. 2022 Jul 12;18:699-719. doi: 10.2147/TCRM.S266031. eCollection 2022. Ther Clin Risk Manag. 2022. PMID: 35855752 Free PMC article. Review.
Broad-based immune-suppressants like corticosteroids are effective in controlling MG; however, their long-term use can be associated with significant adverse effects. Advances in translational research have led to the development of more directed therapeutic agents that ar …
Broad-based immune-suppressants like corticosteroids are effective in controlling MG; however, their long-term use can be associated …
Effect of riluzole on weight in short-term and long-term survivors of amyotrophic lateral sclerosis.
Thakor K, Naud S, Howard D, Tandan R, Waheed W. Thakor K, et al. Among authors: tandan r. Amyotroph Lateral Scler Frontotemporal Degener. 2021 Aug;22(5-6):360-367. doi: 10.1080/21678421.2021.1874992. Epub 2021 Jan 20. Amyotroph Lateral Scler Frontotemporal Degener. 2021. PMID: 33467943
Materials and Methods: Using data from the National ALS Center of Excellence clinic database at the University of Vermont Medical Center, we stratified 244 patients into cohorts based on riluzole use, and duration of survival from the baseline visit into short-term (3 year …
Materials and Methods: Using data from the National ALS Center of Excellence clinic database at the University of Vermont Medical Center, we …
'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF; REGAIN study group. Vissing J, et al. J Neurol. 2020 Jul;267(7):1991-2001. doi: 10.1007/s00415-020-09770-y. Epub 2020 Mar 18. J Neurol. 2020. PMID: 32189108 Free PMC article. Clinical Trial.
At extension study week 130, similar proportions of patients in the eculizumab/eculizumab and placebo/eculizumab groups achieved 'minimal symptom expression' (MG-ADL: 22.9% and 27.8%, respectively, p = 0.7861; MG-QOL15: 14.3% and 19.4%, respectively, p = 0.7531). The long-term …
At extension study week 130, similar proportions of patients in the eculizumab/eculizumab and placebo/eculizumab groups achieved 'minimal sy …
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group. Muppidi S, et al. Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8. Muscle Nerve. 2019. PMID: 30767274 Free PMC article.
We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. METHODS: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients. ...Patients who had received placebo during RE …
We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. METHODS: E …
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.
Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group. Wolfe GI, et al. Among authors: tandan r. Lancet Neurol. 2019 Mar;18(3):259-268. doi: 10.1016/S1474-4422(18)30392-2. Epub 2019 Jan 25. Lancet Neurol. 2019. PMID: 30692052 Free PMC article. Clinical Trial.
BACKGROUND: The Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone (MGTX) showed that thymectomy combined with prednisone was superior to prednisone alone in improving clinical status as measured by the Quantitative Myasthenia Gravis (QMG) score i …
BACKGROUND: The Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone (MGTX) showed that thymectomy combined w …
Relationship of creatine kinase to body composition, disease state, and longevity in ALS.
Gibson SB, Kasarskis EJ, Hu N, Pulst SM, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, Kryscio RJ, Bromberg MB. Gibson SB, et al. Among authors: tandan r. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):473-7. doi: 10.3109/21678421.2015.1062516. Epub 2015 Aug 27. Amyotroph Lateral Scler Frontotemporal Degener. 2015. PMID: 26312548 Free PMC article.
We analyzed data from 80 ALS patients from a 48-week non-interventional longitudinal multicenter nutrition study with long term follow-up. The overall mean CK was 214 191.8 U/l (range 22-1992 U/l). ...
We analyzed data from 80 ALS patients from a 48-week non-interventional longitudinal multicenter nutrition study with long term follo …
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis.
Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, Jacobs M, Rothstein JD, Appel SH, Pascuzzi RM, Heiman-Patterson TD, Donofrio PD, David WS, Russell JA, Tandan R, Pioro EP, Felice KJ, Rosenfeld J, Mandler RN, Sachs GM, Bradley WG, Raynor EM, Baquis GD, Belsh JM, Novella S, Goldstein J, Hulihan J; Northeast ALS Consortium. Cudkowicz ME, et al. Among authors: tandan r. Neurology. 2003 Aug 26;61(4):456-64. doi: 10.1212/wnl.61.4.456. Neurology. 2003. PMID: 12939417 Clinical Trial.
OBJECTIVE: To determine if long-term topiramate therapy is safe and slows disease progression in patients with ALS. ...
OBJECTIVE: To determine if long-term topiramate therapy is safe and slows disease progression in patients with ALS. ...
Topical capsaicin in painful diabetic neuropathy. Effect on sensory function.
Tandan R, Lewis GA, Badger GB, Fries TJ. Tandan R, et al. Diabetes Care. 1992 Jan;15(1):15-8. doi: 10.2337/diacare.15.1.15. Diabetes Care. 1992. PMID: 1737537 Clinical Trial.
Further studies in more subjects are warranted to ensure the long-term safety of capsaicin for pain relief in humans....
Further studies in more subjects are warranted to ensure the long-term safety of capsaicin for pain relief in humans....
11 results